Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
Orasis Pharmaceuticals announced the appointment of Richard L. Lindstrom, MD, Eric D. Donnenfeld, MD, and John Berdahl, MD, to its scientific advisory board. Dr. Lindstrom, Dr. Donnenfeld, and Dr. Berdahl have joined existing scientific advisory board members Sheri Rowen, MD, and Michael Korenfeld, MD. The scientific advisory board of Orasis now consists of five board-certified ophthalmologists and key opinion leaders in the ophthalmology field.
“We are honored to have three leading experts in ophthalmology join the Orasis scientific advisory board,” Elad Kedar, chief executive officer of Orasis, said in a company news release. “Dr. Lindstrom, Dr. Donnenfeld, and Dr. Berdahl bring comprehensive experience and expertise in ophthalmology research and clinical studies, as well as developing innovative solutions in the biopharma industry. Together with our existing scientific advisory board members, Dr. Sheri Rowen and Dr. Michael Korenfeld, the guidance of this team will serve to accelerate the clinical development and ensure the potential success of CSF-1, a corrective eye drop to improve quality of life for individuals with presbyopia by providing an alternative to reading glasses.”
Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in ophthalmology. He is founder and attending surgeon at Minnesota Eye Consultants, adjunct professor emeritus at the University of Minnesota department of ophthalmology, a trustee of the University of Minnesota Foundation, visiting professor at University of California Irvine, Gavin Herbert Eye Institute and global chief medical editor of Ocular Surgery News. He holds over 40 patents for ophthalmology innovations. Dr. Lindstrom completed his medical degree and residency at the University of Minnesota Medical School followed by 2 years of fellowship training in cornea, external disease, cataract surgery, refractive surgery and glaucoma.
Dr. Donnenfeld is a trustee of the Dartmouth Medical School, a clinical professor of ophthalmology at New York University, a national medical director of TLC laser centers, surgical director of the Lions Eye Bank for Long Island, and editor-in-chief of EyeWorld. He is a fellow of the American Academy of Ophthalmology and has received its various awards including the Life Time Achievement Award. He has been involved in over 60 FDA monitored clinical studies. Dr. Donnenfeld previously served as president of ASCRS and many other professional societies. He was a chief resident at Manhattan Eye, Ear and Throat Hospital and received his medical degree from the Dartmouth Medical School.
Dr. Berdahl is a board-certified ophthalmologist and is widely regarded as one of the leading international cataract surgeons, having performed more than 25,000 eye surgeries around the globe. He has been involved in numerous FDA monitored clinical trials. He has developed some of the most exciting technologies in ophthalmology such as the first non-surgical, non-pharmacologic solution to lower eye pressure for glaucoma treatment. Dr. Berdahl founded Equinox, astigmatismfix.com, and co-founded ExpertOpinion.MD. He completed his fellowship at Minnesota Eye Consultants, his residency at Duke University, and an internship at the Mayo Clinic. Dr. Berdahl received his medical degree from the Mayo Medical School.